Dave sits down with nurse practitioner and former Retatrutide clinical trial participant David White to break down the biggest obesity headlines from the 2026 American Diabetes Association Conference. Together, they explore the latest data on Retatrutide&#x27;s potential to deliver bariatric surgery-level weight loss, improve cardiometabolic health, and reshape the future of obesity and type 2 diabetes treatment.<br><br>otplinks.com

Retatrutide Just Reached Bariatric Surgery Results

On The Pen GLP-1 News

# Full Transcript

**Podcast:** On The Pen GLP-1 News

## Participants

- **Dave Knapp** (On The Pen)
- **David White** (Nurse Practitioner (Michigan))

## Transcript

Last week was the American Diabetes Association Conference and so much news came out of that event. But the main headline leaving that massive conference was really the topic of Retatrutide, a topic that we've discussed for the last three and a half years here at On The Pen. And really, we are right around the corner from approval, which means we are at that time where we're getting so much data

to try to process as patients living with the disease of obesity. Is this the next thing that you will be on and why? And in order to really unpack this conversation, I thought it was best to talk to somebody who really understands the science. And so I invited a longtime acquaintance through Twitter and follower of On The Pen. David White is a nurse practitioner out of the state of Michigan and self-proclaimed Retatrutide,

glucagon nerd, and he is deep in the data on this stuff and was present at ADA to learn all about all things Retatrutide. So we're going to invite David White into On The Pen to discuss this year's ADA conference. David, welcome to On The Pen. Hey, thanks for having me. Yeah, super exciting to have you here.

I have followed you pretty closely over the last couple of years, and really, we've kind of gone back and forth over time to find the right time to have you on the program. And I can think of no better time than now. David, why don't you give everybody a little bit of a background about yourself, who you are, what you do, and how you became the sort of go-to source on Retatrutide information on Twitter? Sure. So, like you said, I'm a nurse practitioner.

I primarily work in primary care. And back when I was in nurse practitioner school, I was doing my master's, my final master's project thesis, whatever you want to call it, on how GLP-1 meds work to kind of connect the brain and the gut and pancreas and all that.

And just by happenstance, a researcher, Juan Pablo Frias, who's, if you look on any of the recent, like Lilly or even he does Novo, he kind of works for all the big cardiometabolic companies. And he's a lead researcher. And so I got a chance to interview him. And, you know, he was like, hey, you know, we have this trial enrolling. If you're curious, you know, this is the site in your area.

And so that happened to be Triumph 1. And the rest is history after I called that site. You know, did the 80 weeks in the trial, was on the 12 milligram arm, lost about 30% of my body weight. And as we'll see, that was pretty average for this trial when we get to talking about it.

And that kind of drove the obsession or interest from there. So, yeah. Yeah. So I think that's the biggest, you know, unique perspective that you bring to this. It's not, I mean, we talk to a lot of providers about all things, nutrient-stimulated hormone, obesity medications. Yeah.

But it ...

Retatrutide Just Reached Bariatric Surgery Results

Transcript

Built for investment professionals

Every day you wait, your competitors are finding
edge in conversations you're not hearing.

Retatrutide Just Reached Bariatric Surgery Results

Transcript

Built for investment professionals

Every day you wait, your competitors are findingedge in conversations you're not hearing.

Every day you wait, your competitors are finding
edge in conversations you're not hearing.